The firm currently focuses on metabolic disorders, specifically targeting post-bariatric hypoglycemia and gastroparesis. Its primary asset, mizaglifozin, is undergoing phase 1 and 2 evaluations to determine its efficacy for these conditions, as well as GIP-dependent Cushing's Syndrome. While the company has yet to disclose the volume of shares or the anticipated pricing for the offering, the proceeds are earmarked for advancing this drug candidate, funding broader research initiatives, and covering operational expenses, including payroll and executive bonuses.
In section Market Quotes
Vogenx Targets Nasdaq IPO to Advance Metabolic Drug Pipeline
Clinical-stage biopharmaceutical developer Vogenx has officially filed for an initial public offering, seeking to secure fresh capital to propel its lead drug candidate through clinical trials. The company intends to list its shares on the Nasdaq Capital Market under the ticker symbol VOGX, according to regulatory filings submitted Wednesday.
Comments (0)
No comments yet. Be the first!